-
Some X-factor inhibitors, which have the advantage to be given orally in a fixed dose and don’t require any coagulation monitoring (differently from warfarin) are under study. Some examples of these drugs are rivaroxaban and apixaban. In a double-blind trial sponsored by pharmaceutical industry, [...]
-
There are not clear data yet on the incidence and the risk factors of a post-thrombotic syndrome after an episode of deep venous thrombosis (DVT). Through a prospective cohort trial, 387 patients with DVT in eight hospitals in Canada have been treated with heparin followed by warfarin and monitored [...]
-
The American Academy of Family Physicians and the American College of Physicians, according to published evidences, issued some guidelines on the diagnosis of venous thromboembolism in general practice. In this document, the following behavioural advises are given:
1. Use validated predictive [...]
-
The standard treatment of Kawasaki disease uses intravenous immunoglobulins associated with ASA, while favourable results obtained with cortisone in complicated forms of the disease have driven some clinicians to add these substances to the basic therapy of the disease. In an American [...]
-
According to some studies on animals it seems that the renin-angiotensin system comes into play in favouring the formation of abdominal aortic aneurysms (AAA); consequently, the use of ACE-inhibitors could be able to prevent their formation and progression. To verify this hypothesis in humans, in [...]
-
In the last decade, thromboembolism therapy has seen the shift from the use of unfractionated heparin administered by endovenous route and low-molecular-weight heparin injected under the skin, presenting the advantage of being injected also at home and of not having the need of a coagulation [...]
-
Some patients suffering from venous thromboembolism after incur recurrent episodes of this disease. As to set a long-term anticoagulant therapy is associated to important hemorrhagic risks, it would be very useful to rely upon a test capable to identify patients in whom this recurrence risk is [...]